These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38393441)

  • 21. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A national registry-based study of ethnic differences in people with multiple sclerosis in Iran.
    Ashtari F; Kavosh A; Baghbanian SM; Hosseini Nejad Mir N; Hosseini S; Razazian N; Majdinasab N; Farajzadegan Z; Shaygannejad V; Adibi I; Eskandarieh S; Sahraian MA
    Clin Neurol Neurosurg; 2024 Apr; 239():108216. PubMed ID: 38490075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.
    Hohol MJ; Orav EJ; Weiner HL
    Mult Scler; 1999 Oct; 5(5):349-54. PubMed ID: 10516779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining reliable disability outcomes in multiple sclerosis.
    Kalincik T; Cutter G; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Oreja-Guevara C; Boz C; Pucci E; Bergamaschi R; Lechner-Scott J; Alroughani R; Van Pesch V; Iuliano G; Fernandez-Bolaños R; Ramo C; Terzi M; Slee M; Spitaleri D; Verheul F; Cristiano E; Sánchez-Menoyo JL; Fiol M; Gray O; Cabrera-Gomez JA; Barnett M; Butzkueven H
    Brain; 2015 Nov; 138(Pt 11):3287-98. PubMed ID: 26359291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Burman J; Zelano J
    Neurology; 2017 Dec; 89(24):2462-2468. PubMed ID: 29117950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and demographic characteristics of late-onset multiple sclerosis: LOMS-TR study.
    Sıvacı AÖ; Seferoğlu M; Piri Çınar B; Uzunköprü C; Beckmann Y; Güngör Doğan İ; Çetinkaya Tezer D; Tunç A; Ethemoğlu Ö; Gümüş H; Açıkgöz M; Yalaz Tekan Ü; Demir S
    Mult Scler Relat Disord; 2024 Apr; 84():105469. PubMed ID: 38341979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A CLINICO-EPIDEMIOLOGICAL STUDY OF MULTIPLE SCLEROSIS IN MOSUL CITY, IRAQ.
    Taher Y; Ahmed M; Majdal H
    Georgian Med News; 2023; (340-341):47-52. PubMed ID: 37805872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disability progression in multiple sclerosis: a Tunisian prospective cohort study.
    Hentati E; Ben Sassi S; Nabli F; Mabrouk T; Zouari M; Hentati F
    Neurol Sci; 2018 May; 39(5):879-884. PubMed ID: 29476286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of patients with multiple sclerosis enrolled in a new registry in Egypt.
    Zakaria M; Zamzam DA; Abdel Hafeez MA; Swelam MS; Khater SS; Fahmy MF; Abdel Hady A; Fouad MM; Abdel Nasser A; Aref H; Gadallah M
    Mult Scler Relat Disord; 2016 Nov; 10():30-35. PubMed ID: 27919495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disability profile of MS did not change over 10 years in a population-based prevalence cohort.
    Pittock SJ; Mayr WT; McClelland RL; Jorgensen NW; Weigand SD; Noseworthy JH; Rodriguez M
    Neurology; 2004 Feb; 62(4):601-6. PubMed ID: 14981177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
    Kearney H; Schneider T; Yiannakas MC; Altmann DR; Wheeler-Kingshott CA; Ciccarelli O; Miller DH
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):608-14. PubMed ID: 25097217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of multiple sclerosis relapses on progression diminishes with time.
    Tremlett H; Yousefi M; Devonshire V; Rieckmann P; Zhao Y;
    Neurology; 2009 Nov; 73(20):1616-23. PubMed ID: 19890070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple sclerosis: clinical characteristics and disability progression in Moroccan children.
    Ait Ben Haddou E; Alhyan M; Aasfara J; Regragui W; Ibrahimi A; Razine R; Abouqal R; Benomar A; Yahyaoui M
    J Neurol Sci; 2014 Nov; 346(1-2):128-32. PubMed ID: 25216553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
    Rudick RA; Lee JC; Nakamura K; Fisher E
    J Neurol Sci; 2009 Jul; 282(1-2):106-11. PubMed ID: 19100997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.